Kassner U - Search Results

1

[Diagnostics and treatment of statin-associated muscle symptoms].

Kassner U, Grunwald S, Spira D, Buchmann N, Bobbert T, Gazzerro E, Hollstein T, Spuler S, Steinhagen-Thiessen E. Kassner U, et al. Internist (Berl). 2021 Aug;62(8):827-840. doi: 10.1007/s00108-021-01059-0. Epub 2021 Jun 18. Internist (Berl). 2021. PMID: 34143250 Review. German.

2

[When cholesterol lowering drugs should not be too expensive. Statins are especially effective in secondary prevention].

Thomas HP, Kassner U, Steinhagen-Thiessen E. Thomas HP, et al. Among authors: kassner u. MMW Fortschr Med. 2000 Jul 27;142(30):33-4. MMW Fortschr Med. 2000. PMID: 10955017 German. No abstract available.

3

DALI LDL-apheresis: anticoagulation with r-hirudin in a patient with heparin-induced thrombocytopenia (HIT II).

Thomas HP, Kassner U, Schliesser C, Steinhagen-Thiessen E. Thomas HP, et al. Among authors: kassner u. Int J Artif Organs. 2000 Sep;23(9):637-41. Int J Artif Organs. 2000. PMID: 11059887

4

[Lipoprotein(a): epidemiology and therapeutic approaches].

Kassner U, Thomas HP, Steinhagen-Thiessen E. Kassner U, et al. Dtsch Med Wochenschr. 2000 Nov 3;125(44):1337-43. doi: 10.1055/s-2000-8077. Dtsch Med Wochenschr. 2000. PMID: 11109417 Review. German. No abstract available.

5

Two novel LDL receptor mutations in familial hypercholesterolemia: C122Y and E296X.

Genschel J, Thomas HP, Kassner U, Lochs H, Steinhagen-Thiessen E, Schmidt HH. Genschel J, et al. Among authors: kassner u. Hum Mutat. 2001 Apr;17(4):354. doi: 10.1002/humu.44. Hum Mutat. 2001. PMID: 11295843 No abstract available.

6

Autosomal recessive hypercholesterolemia in three sisters with phenotypic homozygous familial hypercholesterolemia: diagnostic and therapeutic procedures.

Thomas HP, Vogt A, Wilund KR, Schliesser C, Steinhagen-Thiessen E, Kassner U. Thomas HP, et al. Among authors: kassner u. Ther Apher Dial. 2004 Aug;8(4):275-80. doi: 10.1111/j.1526-0968.2004.00143.x. Ther Apher Dial. 2004. PMID: 15274677

7

Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study.

Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E; NAUTILUS Study Group. Vogt A, et al. Among authors: kassner u. Curr Med Res Opin. 2006 Feb;22(2):417-25. doi: 10.1185/030079906x89766. Curr Med Res Opin. 2006. PMID: 16466614 Clinical Trial.

8

[Safety and tolerability of nicotinic acid. Results of the multicenter, open, prospective NAUTILUS study].

Vogt A, Kassner U, Hostalek U, Peiter A, Steinhagen-Thiessen E. Vogt A, et al. Among authors: kassner u. MMW Fortschr Med. 2006 May 4;148(18):41. MMW Fortschr Med. 2006. PMID: 16736688 German. No abstract available.

9

Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan).

Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. Vogt A, et al. Among authors: kassner u. Int J Clin Pract. 2007 Nov;61(11):1914-21. doi: 10.1111/j.1742-1241.2007.01514.x. Int J Clin Pract. 2007. PMID: 17935550 Review.

10

Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.

Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. Vogt A, et al. Among authors: kassner u. Vasc Health Risk Manag. 2007;3(4):467-79. doi: 10.2147/vhrm.s1023. Vasc Health Risk Manag. 2007. PMID: 17969377 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

65 results

Search Page

Filters